Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer.
Marcelo MorenoJúlia Salles OliveiraRafael Canfield BrianeseDouglas Guedes de CastroSolange Moraes SanchesGiovana Tardin TorrezanKarina Miranda SantiagoMarina De BrotVladmir Cláudio Cordeiro de LimaFabiana Baroni Alves MakdissiJose Claudio Casali-da-RochaVinicius Fernando CalsavaraDirce Maria CarraroPublished in: Cancer medicine (2023)
Patients with TNBC and PV in the BRCA2 gene had higher frequencies of secondary bone involvement and CNS in the course of the disease. However, the BRCA2 PV did not represent an independent outcome predictor of metastases and overall survival. Efforts to increase the number of BRCA2 carriers among TNBC patients are crucial for determining their risk of developing bone and CNS metastases compared to BRCA2 noncarriers.